{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T09:31:13Z","timestamp":1765704673112,"version":"3.48.0"},"reference-count":31,"publisher":"BMJ","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pathol"],"published-print":{"date-parts":[[1999,5]]},"abstract":"<jats:p>AIMS: To compare the efficacy of and tolerance to oral fluconazole and intraconazole in preventing fungal infection in neutropenic patients with haematological malignancies. PATIENTS: 213 consecutive, afebrile adult patients treated with or without autologous stem cell transplantation for haematological malignancies. METHODS: A randomised, double blind, single centre study. Patients were randomly assigned to receive fluconazole 50 mg or itraconazole 100 mg, both twice daily in identical capsules. An intention to treat analysis was performed on 202 patients, 101 in each group. RESULTS: Microbiologically documented systemic fungal infections occurred in four patients in each group. Clinical fungal infection was thought to be present in seven recipients of fluconazole and four of itraconazole. In all 202 patients, 29 proceeded to intravenous amphotericin (amphotericin B), 16 in the fluconazole group and 13 in the itraconazole group. Superficial fungal infection was seen only in three non-compliant patients in the fluconazole group. All these infections were oral. No major differences were noted in the isolates of fungi in mouth washes and fecal samples. Overall mortality was 8.9% (18 deaths; seven in the fluconazole group, 11 in the itraconazole group). Mortality from microbiologically and clinically documented fungal infection was 4.5% (nine deaths; three in the fluconazole group, six in the itraconazole group). Median time to suspected or proven fungal infection was 16 days in both groups. None of these comparisons reached statistical significance (p &lt; 0.05). No major clinical toxicity was noted and compliance was excellent. CONCLUSIONS: In neutropenic patients treated for haematological malignancies with or without autologous stem cell transplantation, fluconazole and itraconazole in low doses result in a similar low frequency of fungal disease. Fluconazole may be the preferable drug because of the smaller number of capsules and lack of need for timing relative to meals.<\/jats:p>","DOI":"10.1136\/jcp.52.5.376","type":"journal-article","created":{"date-parts":[[2008,12,31]],"date-time":"2008-12-31T19:05:02Z","timestamp":1230750302000},"page":"376-380","source":"Crossref","is-referenced-by-count":59,"title":["Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology."],"prefix":"10.1136","volume":"52","author":[{"given":"P C","family":"Huijgens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A M","family":"Simoons-Smit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A C","family":"van Loenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Prooy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"van Tinteren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G J","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A R","family":"Jonkhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[1999,5,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0002-9343(82)90594-0","article-title":"Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia","volume":"72","author":"Pizzo, P.A.; Robichaud, K.J.; Gill, F.A.","year":"1982","unstructured":"Pizzo PA, Robichaud KJ, Gill FA, et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101\u201311.","journal-title":"Am J Med"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/0002-9343(89)90441-5","article-title":"EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients","volume":"86","year":"1989","unstructured":"EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:668\u201372.","journal-title":"Am J Med"},{"key":"ref_3","first-page":"2267","article-title":"Infections in patients with acute leukemia","volume-title":"Principles and practice of infectious diseases","author":"Meunier, F.","year":"1990","unstructured":"Meunier F. Infections in patients with acute leukemia. In: Mandell GL, Douglas RG, Bennett JE, eds. Principles and practice of infectious diseases, 3rd ed. New York: Churchill Livingstone, 1990:2267\u201391.","edition":"3rd ed"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/clinids\/13.3.487","article-title":"Candida and Aspergillus infections in immunocompromised patients: an overview","volume":"13","author":"Saral, R.","year":"1991","unstructured":"Saral R. Candida and Aspergillus infections in immunocompromised patients: an overview. Rev Infect Dis 1991;13: 487\u201392.","journal-title":"Rev Infect Dis"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJM199305063281808","article-title":"Management of fever in patients with cancer and treatment-induced neutropenia","volume":"328","author":"Pizzo, P.A.","year":"1993","unstructured":"Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328: 1323\u201332.","journal-title":"N Engl J Med"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0889-8588(18)30268-5","article-title":"Management of infection in patients with acute leukemia","volume":"7","author":"Wade, J.C.","year":"1993","unstructured":"Wade JC. Management of infection in patients with acute leukemia. Hematol Oncol Clin North Am 1993;7:293\u2013315.","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/clinids\/18.3.273","article-title":"Infections in bone marrow transplant recipients","volume":"18","author":"Sable, C.A.; Donowitz, G.R.","year":"1994","unstructured":"Sable CA, Donowitz GR. Infections in bone marrow transplant recipients. Clin Infect Dis 1994;18:273\u201384.","journal-title":"Clin Infect Dis"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1056\/NEJM197303082881001","article-title":"Protective environments and prophylactic antibiotics. A prospective controlled study of their utility in the therapy of acute leukemia","volume":"288","author":"Levine, A.S.; Siegel, S.E.; Schreiber, A.D.","year":"1973","unstructured":"Levine AS, Siegel SE, Schreiber AD, et al. Protective environments and prophylactic antibiotics. A prospective controlled study of their utility in the therapy of acute leukemia. N Engl J Med 1973;288:477\u201382.","journal-title":"N Engl J Med"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.7326\/0003-4819-82-3-351","article-title":"Infection prevention in acute nonlymphocytic leukemia. Laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis","volume":"82","author":"SchimpV, S.C.; Greene, W.H.; Young, V.M.","year":"1975","unstructured":"SchimpV SC, Greene WH, Young VM, et al. Infection prevention in acute nonlymphocytic leukemia. Laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis. Ann Intern Med 1975;82:351\u20137.","journal-title":"Ann Intern Med"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/mpo.2950030309","article-title":"Oral anticandidal prophylaxis in patients undergoing chemotherapy for acute leukemia","volume":"3","author":"Williams, C.; Whitehouse, J.M.A.; Lister, T.A.","year":"1977","unstructured":"Williams C, Whitehouse JMA, Lister TA, et al. Oral anticandidal prophylaxis in patients undergoing chemotherapy for acute leukemia. Med Pediatr Oncol 1977;3:275\u2013 9.","journal-title":"Med Pediatr Oncol; 9"},{"key":"ref_11","first-page":"139","article-title":"Nystatin prophylaxis of fungal colonization and infection in granulocytopenic patients: Correlation of colonization and clinical outcome","volume":"8","author":"Buchanan, A.G.; Riben, P.D.; Rayner, E.N.","year":"1985","unstructured":"Buchanan AG, Riben PD, Rayner EN, et al. Nystatin prophylaxis of fungal colonization and infection in granulocytopenic patients: Correlation of colonization and clinical outcome. Clin Invest Med 1985;8:139\u201344.","journal-title":"Clin Invest Med"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJM199203263261301","article-title":"A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation","volume":"326","author":"Goodman, J.L.; Winston, D.J.; Greenfield, R.A.","year":"1992","unstructured":"Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845\u201351.","journal-title":"N Engl J Med"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"495","DOI":"10.7326\/0003-4819-118-7-199304010-00003","article-title":"Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebocontrolled, double-blind, multicenter trial","volume":"118","author":"Winston, D.J.; Chandrasekar, P.H.; Lazarus, H.M.","year":"1993","unstructured":"Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebocontrolled, double-blind, multicenter trial. Ann Intern Med 1993;118:495\u20139.","journal-title":"Ann Intern Med"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/BF03259575","article-title":"Chemoprophylaxis of fungal infections in granocytopenic patients using fluconazole vs oral amphotericin B","volume":"3","author":"Meunier, F.; Aoun, M.; Janssens, C.","year":"1991","unstructured":"Meunier F, Aoun M, Janssens C, et al. Chemoprophylaxis of fungal infections in granocytopenic patients using fluconazole vs oral amphotericin B. Drug Invest 1991;3:258\u201365.","journal-title":"Drug Invest"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/jac\/27.3.369","article-title":"A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukemia","volume":"27","author":"Rozenberg-Arska, M.; Dekker, A.W.; Branger, J.","year":"1991","unstructured":"Rozenberg-Arska M, Dekker AW, Branger J, et al. A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukemia. J Antimicrob Chemother 1991;27:369\u2013 76.","journal-title":"J Antimicrob Chemother"},{"key":"ref_16","first-page":"919","article-title":"Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation","volume":"14","author":"Alangaden, G.; Chandrasekar, P.H.; Bailey, E.","year":"1994","unstructured":"Alangaden G, Chandrasekar PH, Bailey E, et al, and the Bone Marrow Transplantation Team. Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. Bone Marrow Transplant 1994;14:919\u201324.","journal-title":"Bone Marrow Transplant"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-120-11-199406010-00003","article-title":"The GIMENA Infection Program. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B","volume":"120","author":"Menichetti, F.; Del Favero, A.; Martino, P.","year":"1994","unstructured":"Menichetti F, Del Favero A, Martino P, et al, and The GIMENA Infection Program. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. Ann Intern Med 1994; 120:913\u201318.","journal-title":"Ann Intern Med"},{"key":"ref_18","first-page":"1","article-title":"Antifungal prophylaxis during neutropenia or allogeneic bone marrow transplantation: what is the state of the art?","volume":"38","author":"Denning, D.W.; Donnelly, J.P.; Hellreigel, K.P.","year":"1991","unstructured":"Denning DW, Donnelly JP, Hellreigel KP, et al. Antifungal prophylaxis during neutropenia or allogeneic bone marrow transplantation: what is the state of the art? Chemotherapy 1991;38(suppl 1):43\u20137.","journal-title":"Chemotherapy"},{"key":"ref_19","first-page":"1","article-title":"Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels","volume":"32","author":"Boogaerts, M.A.; Verhoef, G.E.; Zachee, P.","year":"1989","unstructured":"Boogaerts MA, Verhoef GE, Zachee P, et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989;32(suppl 1):103\u20135.","journal-title":"Mycoses"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/10428199309067926","article-title":"EYcacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double-blind, placebo controlled study","volume":"11","author":"Vreugdenhil, G.; Van Dijke, B.J.; Donnelly, P.","year":"1994","unstructured":"Vreugdenhil G, Van Dijke BJ, Donnelly P, et al. EYcacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double-blind, placebo controlled study. Leuk Lymphoma 1994;11:353\u20139.","journal-title":"Leuk Lymphoma"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/ajhp\/52.2.164","article-title":"Fluconazole for antifungal prophylaxis in chemotherapy-induced neutropenia","volume":"52","author":"Preston, S.L.; Briceland, L.L.","year":"1995","unstructured":"Preston SL, Briceland LL. Fluconazole for antifungal prophylaxis in chemotherapy-induced neutropenia. Am J Health Syst Pharm 1995;52:164\u201373.","journal-title":"Am J Health Syst Pharm"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1136\/bmj.314.7089.1238","article-title":"Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia","volume":"314","author":"G\u00f8tzsche, P.C.; Johansen, H.K.","year":"1997","unstructured":"G\u00f8tzsche PC, Johansen HK. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. BMJ 1997;314:1238\u201344.","journal-title":"BMJ"},{"key":"ref_23","first-page":"926","article-title":"The prophylactic use of fluconazole 50 vs 100 mg daily in haematological malignancies","volume":"6","author":"Huijgens, P.C.; van, Loenen A.C.; Simoons-Smit, A.M.","year":"1993","unstructured":"Huijgens PC, Loenen AC van, Simoons-Smit AM, et al. The prophylactic use of fluconazole 50 vs 100 mg daily in haematological malignancies. Eur J Cancer 1993;6:926\u20137.","journal-title":"Eur J Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000239322","article-title":"non\u2013albicans Candida spp, and other fungal organisms in a sixty-bed National Cancer Center in 1989\u2013 1993: no association with the use of fluconazole","volume":"41","author":"Kunora, A.; Trupl, I.; Spanik, S.","year":"1995","unstructured":"Kunora A, Trupl I, Spanik S, et al. Candida glabrata, Candida krusei, non\u2013albicans Candida spp, and other fungal organisms in a sixty-bed National Cancer Center in 1989\u2013 1993: no association with the use of fluconazole. Chemotherapy 1995;41:39\u201344.","journal-title":"Chemotherapy"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/clinids\/24.2.235","article-title":"Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections","volume":"24","author":"Rex, H.; Pfaller, M.A.; Galgiani, J.N.","year":"1997","unstructured":"Rex H, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Clin Infect Dis 1997;24:235\u201347.","journal-title":"Clin Infect Dis"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/jac\/34.2.247","article-title":"Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients","volume":"34","author":"Prentice, A.G.; Warnock, D.W.; Johnson, S.A.N.","year":"1994","unstructured":"Prentice AG, Warnock DW, Johnson SAN, et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother 1994;34:247\u201352.","journal-title":"J Antimicrob Chemother"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/jac\/36.4.657","article-title":"Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukemia","volume":"36","author":"Prentice, A.G.; Warnock, D.W.; Johnson, S.A.N.","year":"1995","unstructured":"Prentice AG, Warnock DW, Johnson SAN, et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukemia. J Antimicrob Chemother 1995;36:657\u201363.","journal-title":"J Antimicrob Chemother"},{"key":"ref_28","first-page":"1865","article-title":"Fluconazole v itraconazole prophylaxis in neutropenia following therapy for haematological malignancy","volume":"1997","author":"Prentice, A.G.; Morgenstern, G.R.; Prentice, H.G.","unstructured":"Prentice AG, Morgenstern GR, Prentice HG, et al. Fluconazole v itraconazole prophylaxis in neutropenia following therapy for haematological malignancy [abstract]. Am Soc Hematol 1997:1865.","journal-title":"Am Soc Hematol"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.7326\/0003-4819-125-3-199608010-00004","article-title":"Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: eVect of augmented Gram-positive activity on infectious morbidity","volume":"125","author":"Bow, E.J.; Mandell, L.A.; Louie, T.J.","year":"1996","unstructured":"Bow EJ, Mandell LA, Louie TJ, et al. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: eVect of augmented Gram-positive activity on infectious morbidity. Ann Intern Med 1996;125:183\u201390.","journal-title":"Ann Intern Med"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0609.1991.tb00512.x","article-title":"Imipenem-cilastatin for empirical therapy in neutropenic patients with fever: an open study in patients with hematologic malignancies","volume":"46","author":"Huijgens, P.C.; Ossenkoppele, G.J.; Weijers, T.F.","year":"1991","unstructured":"Huijgens PC, Ossenkoppele GJ, Weijers TF, et al. Imipenem-cilastatin for empirical therapy in neutropenic patients with fever: an open study in patients with hematologic malignancies. Eur J Haematol 1991;46:42\u20136.","journal-title":"Eur J Haematol"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/jac\/37.5.975","article-title":"A meta-analysis of clinical studies of imipenem-cilastatin for empirically treating febrile neutropenic patients","volume":"37","author":"Deaney, N.B.; Tate, H.","year":"1996","unstructured":"Deaney NB, Tate H. A meta-analysis of clinical studies of imipenem-cilastatin for empirically treating febrile neutropenic patients. J Antimicrob Chemother 1996;37:975\u201386.","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp.52.5.376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T09:29:25Z","timestamp":1765704565000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp.52.5.376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,5]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[1999,5,1]]},"published-print":{"date-parts":[[1999,5]]}},"alternative-id":["10.1136\/jcp.52.5.376"],"URL":"https:\/\/doi.org\/10.1136\/jcp.52.5.376","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"type":"print","value":"0021-9746"},{"type":"electronic","value":"1472-4146"}],"subject":[],"published":{"date-parts":[[1999,5]]}}}